| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 57 | 2021 | 638 | 6.760 |
Why?
|
| Glioblastoma | 25 | 2021 | 156 | 4.360 |
Why?
|
| Glioma | 29 | 2020 | 136 | 3.920 |
Why?
|
| Central Nervous System Neoplasms | 7 | 2014 | 29 | 2.260 |
Why?
|
| Antineoplastic Agents | 19 | 2020 | 608 | 2.200 |
Why?
|
| Antineoplastic Agents, Alkylating | 12 | 2019 | 40 | 1.820 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2021 | 367 | 1.570 |
Why?
|
| Dacarbazine | 11 | 2017 | 29 | 1.500 |
Why?
|
| Radiotherapy | 12 | 2019 | 82 | 1.250 |
Why?
|
| Humans | 96 | 2021 | 32005 | 1.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2017 | 22 | 1.060 |
Why?
|
| Middle Aged | 66 | 2021 | 11817 | 1.030 |
Why?
|
| Neoplasms | 7 | 2018 | 726 | 0.940 |
Why?
|
| Adult | 55 | 2021 | 9345 | 0.830 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2018 | 458 | 0.830 |
Why?
|
| Female | 66 | 2021 | 19959 | 0.800 |
Why?
|
| Aged | 53 | 2021 | 10301 | 0.790 |
Why?
|
| Breast Neoplasms | 7 | 2020 | 765 | 0.760 |
Why?
|
| Treatment Outcome | 16 | 2019 | 3306 | 0.750 |
Why?
|
| Male | 60 | 2020 | 19165 | 0.710 |
Why?
|
| Meningioma | 4 | 2015 | 57 | 0.700 |
Why?
|
| Combined Modality Therapy | 14 | 2018 | 560 | 0.670 |
Why?
|
| Fatigue | 4 | 2015 | 85 | 0.650 |
Why?
|
| Clinical Trials as Topic | 5 | 2018 | 301 | 0.650 |
Why?
|
| Taste Disorders | 3 | 2018 | 4 | 0.610 |
Why?
|
| Olfaction Disorders | 3 | 2018 | 7 | 0.610 |
Why?
|
| Radiation Injuries | 3 | 2019 | 76 | 0.600 |
Why?
|
| Hyperglycemia | 1 | 2017 | 84 | 0.580 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2016 | 101 | 0.550 |
Why?
|
| Endpoint Determination | 1 | 2016 | 20 | 0.540 |
Why?
|
| Quality of Life | 11 | 2019 | 946 | 0.520 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 21 | 0.520 |
Why?
|
| Hemangiopericytoma | 2 | 2013 | 6 | 0.510 |
Why?
|
| Aged, 80 and over | 25 | 2019 | 3990 | 0.500 |
Why?
|
| Radiosurgery | 3 | 2014 | 356 | 0.500 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 112 | 0.500 |
Why?
|
| Follow-Up Studies | 17 | 2018 | 2265 | 0.490 |
Why?
|
| Astrocytoma | 3 | 2018 | 29 | 0.480 |
Why?
|
| Dapsone | 1 | 2014 | 4 | 0.470 |
Why?
|
| Anemia, Hemolytic | 1 | 2014 | 7 | 0.470 |
Why?
|
| Procarbazine | 2 | 2011 | 5 | 0.470 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 21 | 0.470 |
Why?
|
| Lymphoma | 2 | 2011 | 35 | 0.460 |
Why?
|
| Thalidomide | 2 | 2011 | 31 | 0.460 |
Why?
|
| Taste | 1 | 2013 | 17 | 0.450 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 23 | 0.440 |
Why?
|
| Ubiquinone | 1 | 2013 | 7 | 0.440 |
Why?
|
| Influenza Vaccines | 1 | 2014 | 78 | 0.440 |
Why?
|
| Semen | 1 | 2013 | 10 | 0.430 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2012 | 6 | 0.430 |
Why?
|
| Sperm Motility | 1 | 2013 | 8 | 0.430 |
Why?
|
| Smell | 1 | 2013 | 48 | 0.430 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 36 | 0.420 |
Why?
|
| Vitamins | 1 | 2013 | 68 | 0.420 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 28 | 0.420 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2012 | 4 | 0.410 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 85 | 0.410 |
Why?
|
| Melanoma | 1 | 2013 | 164 | 0.400 |
Why?
|
| Pulmonary Embolism | 1 | 2012 | 49 | 0.400 |
Why?
|
| Prognosis | 12 | 2018 | 1497 | 0.390 |
Why?
|
| Medication Adherence | 1 | 2013 | 161 | 0.380 |
Why?
|
| Young Adult | 16 | 2018 | 2636 | 0.360 |
Why?
|
| Indans | 3 | 2020 | 31 | 0.340 |
Why?
|
| Pilot Projects | 5 | 2020 | 545 | 0.340 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2020 | 46 | 0.330 |
Why?
|
| Pain | 2 | 2019 | 288 | 0.330 |
Why?
|
| DNA Methylation | 5 | 2018 | 141 | 0.330 |
Why?
|
| Anticoagulants | 2 | 2012 | 122 | 0.330 |
Why?
|
| DNA Modification Methylases | 4 | 2018 | 11 | 0.330 |
Why?
|
| DNA Repair Enzymes | 4 | 2018 | 14 | 0.330 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2018 | 71 | 0.310 |
Why?
|
| Disease-Free Survival | 9 | 2019 | 317 | 0.310 |
Why?
|
| Meningeal Neoplasms | 3 | 2014 | 49 | 0.280 |
Why?
|
| Administration, Oral | 5 | 2017 | 187 | 0.280 |
Why?
|
| Cognition Disorders | 3 | 2015 | 385 | 0.280 |
Why?
|
| Prospective Studies | 8 | 2020 | 2282 | 0.280 |
Why?
|
| Saliva | 2 | 2018 | 36 | 0.270 |
Why?
|
| Dietary Supplements | 3 | 2018 | 185 | 0.270 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2005 | 2 | 0.260 |
Why?
|
| Nasal Cavity | 1 | 2005 | 6 | 0.260 |
Why?
|
| Nose Neoplasms | 1 | 2005 | 4 | 0.260 |
Why?
|
| Survival Rate | 10 | 2019 | 877 | 0.260 |
Why?
|
| Double-Blind Method | 7 | 2019 | 525 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2017 | 1328 | 0.250 |
Why?
|
| Thromboembolism | 1 | 2004 | 34 | 0.240 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 447 | 0.230 |
Why?
|
| Plant Extracts | 2 | 2017 | 61 | 0.230 |
Why?
|
| Spinal Cord Compression | 1 | 2003 | 7 | 0.230 |
Why?
|
| Maximum Tolerated Dose | 8 | 2018 | 62 | 0.230 |
Why?
|
| Spinal Neoplasms | 1 | 2003 | 22 | 0.230 |
Why?
|
| Hospice Care | 1 | 2003 | 13 | 0.220 |
Why?
|
| Sulfones | 2 | 2020 | 21 | 0.220 |
Why?
|
| Genomics | 3 | 2018 | 85 | 0.220 |
Why?
|
| Anticonvulsants | 6 | 2010 | 65 | 0.220 |
Why?
|
| Home Care Services | 1 | 2003 | 51 | 0.210 |
Why?
|
| Health Services Needs and Demand | 1 | 2003 | 81 | 0.210 |
Why?
|
| Neuropsychological Tests | 3 | 2019 | 371 | 0.210 |
Why?
|
| Salivary Proteins and Peptides | 2 | 2018 | 3 | 0.190 |
Why?
|
| Retrospective Studies | 7 | 2018 | 3509 | 0.190 |
Why?
|
| Camptothecin | 3 | 2008 | 51 | 0.190 |
Why?
|
| Fluorenes | 1 | 2021 | 4 | 0.190 |
Why?
|
| Electromagnetic Fields | 2 | 2018 | 26 | 0.190 |
Why?
|
| Ketones | 1 | 2021 | 11 | 0.190 |
Why?
|
| Neoplastic Stem Cells | 2 | 2021 | 99 | 0.190 |
Why?
|
| Benzazepines | 1 | 2021 | 21 | 0.190 |
Why?
|
| Salvage Therapy | 4 | 2015 | 134 | 0.180 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 412 | 0.180 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2014 | 42 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 208 | 0.180 |
Why?
|
| Time Factors | 7 | 2017 | 2149 | 0.180 |
Why?
|
| Tibial Nerve | 1 | 2020 | 22 | 0.180 |
Why?
|
| Disease Management | 2 | 2018 | 126 | 0.170 |
Why?
|
| Sural Nerve | 1 | 2020 | 28 | 0.170 |
Why?
|
| Taxoids | 1 | 2020 | 59 | 0.170 |
Why?
|
| Median Nerve | 1 | 2020 | 51 | 0.170 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2020 | 51 | 0.170 |
Why?
|
| Vena Cava Filters | 2 | 2012 | 13 | 0.170 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 24 | 0.170 |
Why?
|
| Brain | 3 | 2017 | 951 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 57 | 0.160 |
Why?
|
| Dendritic Cells | 1 | 2019 | 59 | 0.160 |
Why?
|
| Lactoferrin | 1 | 2018 | 3 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 835 | 0.160 |
Why?
|
| Radiodermatitis | 1 | 2018 | 6 | 0.160 |
Why?
|
| Postoperative Complications | 2 | 2014 | 780 | 0.160 |
Why?
|
| Etoposide | 1 | 2017 | 34 | 0.150 |
Why?
|
| Vincristine | 1 | 2017 | 17 | 0.150 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 38 | 0.150 |
Why?
|
| Karnofsky Performance Status | 3 | 2014 | 11 | 0.150 |
Why?
|
| Prednisone | 1 | 2017 | 61 | 0.150 |
Why?
|
| Neuronavigation | 1 | 2017 | 8 | 0.150 |
Why?
|
| Survivors | 2 | 2018 | 163 | 0.150 |
Why?
|
| Electroporation | 1 | 2017 | 14 | 0.150 |
Why?
|
| Tumor Burden | 1 | 2017 | 58 | 0.150 |
Why?
|
| Ablation Techniques | 1 | 2017 | 25 | 0.150 |
Why?
|
| Ephrin-A1 | 1 | 2017 | 11 | 0.150 |
Why?
|
| Cohort Studies | 7 | 2019 | 1817 | 0.150 |
Why?
|
| Receptors, Somatostatin | 2 | 2014 | 5 | 0.150 |
Why?
|
| Doxorubicin | 1 | 2017 | 82 | 0.150 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 4 | 0.150 |
Why?
|
| Ultrasonography | 1 | 2020 | 379 | 0.150 |
Why?
|
| Craniotomy | 1 | 2017 | 46 | 0.150 |
Why?
|
| Cardiac Volume | 1 | 2017 | 13 | 0.140 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 181 | 0.140 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 238 | 0.140 |
Why?
|
| Quinazolines | 1 | 2017 | 38 | 0.140 |
Why?
|
| Calcium Channels, T-Type | 1 | 2017 | 29 | 0.140 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2017 | 53 | 0.140 |
Why?
|
| Piperazines | 1 | 2017 | 54 | 0.140 |
Why?
|
| Micronutrients | 1 | 2017 | 18 | 0.140 |
Why?
|
| Dideoxynucleosides | 1 | 2016 | 1 | 0.140 |
Why?
|
| Genome, Human | 1 | 2017 | 132 | 0.140 |
Why?
|
| Phytotherapy | 2 | 2017 | 38 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 78 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 148 | 0.140 |
Why?
|
| Biopsy | 1 | 2017 | 259 | 0.140 |
Why?
|
| Heart Ventricles | 1 | 2017 | 135 | 0.130 |
Why?
|
| Cranial Irradiation | 2 | 2014 | 93 | 0.130 |
Why?
|
| Central Nervous System | 1 | 2016 | 43 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2017 | 170 | 0.130 |
Why?
|
| Head | 1 | 2016 | 51 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 163 | 0.130 |
Why?
|
| Survival Analysis | 4 | 2011 | 483 | 0.130 |
Why?
|
| Benzhydryl Compounds | 1 | 2015 | 7 | 0.130 |
Why?
|
| Ganglioglioma | 1 | 2015 | 6 | 0.130 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2015 | 31 | 0.130 |
Why?
|
| Radiotherapy Dosage | 2 | 2013 | 101 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2017 | 245 | 0.130 |
Why?
|
| Mutation | 2 | 2017 | 489 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 130 | 0.120 |
Why?
|
| Blood Glucose | 1 | 2017 | 494 | 0.120 |
Why?
|
| Somatostatin | 1 | 2014 | 11 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2014 | 34 | 0.120 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2014 | 7 | 0.120 |
Why?
|
| Inflammation | 1 | 2018 | 530 | 0.120 |
Why?
|
| Indoles | 1 | 2014 | 56 | 0.120 |
Why?
|
| Piperidines | 1 | 2015 | 118 | 0.120 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2014 | 23 | 0.120 |
Why?
|
| Influenza B virus | 1 | 2014 | 20 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 8 | 0.120 |
Why?
|
| Stroke Volume | 1 | 2017 | 348 | 0.120 |
Why?
|
| Epidermal Cyst | 1 | 2013 | 4 | 0.110 |
Why?
|
| Body Composition | 1 | 2016 | 397 | 0.110 |
Why?
|
| Cyclohexanols | 1 | 2013 | 20 | 0.110 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 19 | 0.110 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2013 | 12 | 0.110 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2013 | 37 | 0.110 |
Why?
|
| Receptor, erbB-2 | 1 | 2013 | 65 | 0.110 |
Why?
|
| Blood Cell Count | 1 | 2013 | 29 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 57 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2004 | 49 | 0.110 |
Why?
|
| Hot Flashes | 1 | 2013 | 48 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2013 | 189 | 0.110 |
Why?
|
| Soybean Proteins | 1 | 2013 | 74 | 0.110 |
Why?
|
| Pipecolic Acids | 1 | 2012 | 6 | 0.110 |
Why?
|
| Hirudins | 1 | 2012 | 19 | 0.110 |
Why?
|
| Polysaccharides | 1 | 2012 | 13 | 0.110 |
Why?
|
| Thrombocytopenia | 1 | 2012 | 30 | 0.110 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2013 | 34 | 0.110 |
Why?
|
| Warfarin | 1 | 2012 | 29 | 0.110 |
Why?
|
| Venous Thrombosis | 1 | 2012 | 49 | 0.100 |
Why?
|
| Software | 1 | 2013 | 123 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2013 | 220 | 0.100 |
Why?
|
| Ginkgo biloba | 1 | 2012 | 19 | 0.100 |
Why?
|
| Snake Venoms | 1 | 2012 | 2 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2013 | 633 | 0.100 |
Why?
|
| Mood Disorders | 1 | 2012 | 21 | 0.100 |
Why?
|
| Plant Preparations | 1 | 2012 | 27 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 726 | 0.100 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 247 | 0.100 |
Why?
|
| Patient Participation | 1 | 2013 | 82 | 0.100 |
Why?
|
| Panax | 1 | 2012 | 8 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2020 | 604 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2012 | 100 | 0.100 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 18 | 0.100 |
Why?
|
| Self Administration | 1 | 2013 | 297 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 154 | 0.100 |
Why?
|
| Respiratory Tract Infections | 1 | 2012 | 40 | 0.100 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 77 | 0.100 |
Why?
|
| Mental Status Schedule | 1 | 2011 | 24 | 0.100 |
Why?
|
| Adolescent | 5 | 2018 | 3539 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 214 | 0.090 |
Why?
|
| Medulloblastoma | 1 | 2010 | 7 | 0.090 |
Why?
|
| Immunosuppression | 1 | 2011 | 121 | 0.090 |
Why?
|
| Cerebellar Neoplasms | 1 | 2010 | 11 | 0.090 |
Why?
|
| Poly I-C | 1 | 2010 | 4 | 0.090 |
Why?
|
| Interferon Inducers | 1 | 2010 | 2 | 0.090 |
Why?
|
| Polylysine | 1 | 2010 | 5 | 0.090 |
Why?
|
| Epothilones | 1 | 2010 | 3 | 0.090 |
Why?
|
| Radiation Oncology | 1 | 2010 | 10 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2010 | 8 | 0.090 |
Why?
|
| Pyrazines | 1 | 2010 | 13 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2011 | 472 | 0.090 |
Why?
|
| Disease Progression | 4 | 2018 | 594 | 0.090 |
Why?
|
| Quinolones | 1 | 2008 | 7 | 0.080 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 193 | 0.080 |
Why?
|
| Mice, Nude | 2 | 2020 | 291 | 0.080 |
Why?
|
| Cognition | 2 | 2015 | 555 | 0.080 |
Why?
|
| Pyrrolidines | 1 | 2008 | 12 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 471 | 0.080 |
Why?
|
| Cell Movement | 2 | 2020 | 169 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 762 | 0.080 |
Why?
|
| Phenytoin | 1 | 2008 | 3 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2009 | 86 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 510 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2008 | 67 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2008 | 67 | 0.070 |
Why?
|
| Methylphenidate | 1 | 2007 | 36 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 2 | 2018 | 19 | 0.070 |
Why?
|
| Antioxidants | 2 | 2018 | 115 | 0.070 |
Why?
|
| Stereotaxic Techniques | 1 | 2006 | 23 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 76 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2018 | 81 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 261 | 0.070 |
Why?
|
| Animals | 4 | 2020 | 7541 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2018 | 293 | 0.070 |
Why?
|
| Dalteparin | 1 | 2004 | 1 | 0.060 |
Why?
|
| Supratentorial Neoplasms | 1 | 2004 | 3 | 0.060 |
Why?
|
| Enoxaparin | 1 | 2004 | 20 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2015 | 81 | 0.060 |
Why?
|
| Oxidative Stress | 2 | 2018 | 231 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 918 | 0.060 |
Why?
|
| Heparin | 1 | 2004 | 73 | 0.060 |
Why?
|
| Observer Variation | 2 | 2016 | 105 | 0.060 |
Why?
|
| Suramin | 1 | 2004 | 1 | 0.060 |
Why?
|
| Methotrexate | 1 | 2004 | 64 | 0.060 |
Why?
|
| Laminectomy | 1 | 2003 | 16 | 0.060 |
Why?
|
| Nursing Assessment | 1 | 2003 | 11 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2003 | 45 | 0.060 |
Why?
|
| Decompression, Surgical | 1 | 2003 | 55 | 0.050 |
Why?
|
| Mice | 2 | 2020 | 2484 | 0.050 |
Why?
|
| Focus Groups | 1 | 2003 | 113 | 0.050 |
Why?
|
| Embolization, Therapeutic | 1 | 2003 | 86 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 582 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2015 | 190 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 881 | 0.050 |
Why?
|
| Cytarabine | 1 | 2002 | 55 | 0.050 |
Why?
|
| Life Style | 1 | 2004 | 408 | 0.050 |
Why?
|
| Diet | 1 | 2004 | 391 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2003 | 350 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2004 | 407 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 115 | 0.040 |
Why?
|
| Ankle | 1 | 2020 | 29 | 0.040 |
Why?
|
| Epidermis | 1 | 2020 | 30 | 0.040 |
Why?
|
| Albumins | 1 | 2020 | 45 | 0.040 |
Why?
|
| Electrodiagnosis | 1 | 2020 | 42 | 0.040 |
Why?
|
| Forearm | 1 | 2020 | 43 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2020 | 37 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 67 | 0.040 |
Why?
|
| Wrist | 1 | 2020 | 48 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 353 | 0.040 |
Why?
|
| Leg | 1 | 2020 | 65 | 0.040 |
Why?
|
| Child | 2 | 2017 | 2438 | 0.040 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2019 | 3 | 0.040 |
Why?
|
| Neural Conduction | 1 | 2020 | 91 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 45 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2019 | 43 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 45 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2012 | 463 | 0.040 |
Why?
|
| Immunity, Mucosal | 1 | 2018 | 5 | 0.040 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2018 | 3 | 0.040 |
Why?
|
| Minerals | 1 | 2018 | 14 | 0.040 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2018 | 13 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 276 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 166 | 0.040 |
Why?
|
| RNA Interference | 1 | 2018 | 76 | 0.040 |
Why?
|
| Drug Interactions | 2 | 2008 | 78 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2018 | 42 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 114 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 73 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2018 | 96 | 0.040 |
Why?
|
| Proteomics | 1 | 2018 | 94 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2018 | 122 | 0.040 |
Why?
|
| Iron | 1 | 2018 | 116 | 0.040 |
Why?
|
| Mibefradil | 1 | 2017 | 1 | 0.040 |
Why?
|
| Cell Size | 1 | 2017 | 38 | 0.040 |
Why?
|
| Receptor, EphA2 | 1 | 2017 | 13 | 0.040 |
Why?
|
| Cell Death | 1 | 2017 | 77 | 0.040 |
Why?
|
| Membrane Potentials | 1 | 2017 | 81 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2017 | 81 | 0.040 |
Why?
|
| Astrocytes | 1 | 2017 | 58 | 0.040 |
Why?
|
| DNA Repair | 1 | 2017 | 64 | 0.040 |
Why?
|
| Powders | 1 | 2017 | 8 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2017 | 61 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2017 | 31 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 30 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 547 | 0.040 |
Why?
|
| Diastole | 1 | 2017 | 96 | 0.040 |
Why?
|
| Finite Element Analysis | 1 | 2017 | 82 | 0.040 |
Why?
|
| Risk Factors | 2 | 2015 | 3876 | 0.030 |
Why?
|
| Hydrogels | 1 | 2017 | 121 | 0.030 |
Why?
|
| Skin | 1 | 2018 | 211 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 103 | 0.030 |
Why?
|
| Collagen | 1 | 2017 | 225 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2016 | 16 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 93 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2008 | 93 | 0.030 |
Why?
|
| Abdominal Fat | 1 | 2016 | 50 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 112 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2018 | 476 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2019 | 682 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 82 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1531 | 0.030 |
Why?
|
| Affect | 1 | 2015 | 69 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 1062 | 0.030 |
Why?
|
| Models, Biological | 1 | 2017 | 392 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2014 | 18 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1188 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 276 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 84 | 0.030 |
Why?
|
| Infant | 1 | 2017 | 1061 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 162 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2004 | 149 | 0.030 |
Why?
|
| Memory | 1 | 2015 | 190 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2017 | 1269 | 0.030 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2013 | 3 | 0.030 |
Why?
|
| Thoracic Vertebrae | 1 | 2013 | 42 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 52 | 0.030 |
Why?
|
| Rats | 1 | 2017 | 1595 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 67 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 75 | 0.030 |
Why?
|
| Research Design | 1 | 2015 | 313 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2016 | 349 | 0.030 |
Why?
|
| Integrins | 1 | 2012 | 41 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2014 | 898 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2011 | 32 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 981 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 253 | 0.020 |
Why?
|
| Otitis Media | 1 | 2011 | 23 | 0.020 |
Why?
|
| Craniopharyngioma | 1 | 2010 | 8 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2010 | 41 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 35 | 0.020 |
Why?
|
| Pituitary Neoplasms | 1 | 2010 | 17 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 19 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 684 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 324 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2008 | 25 | 0.020 |
Why?
|
| Incidence | 1 | 2012 | 1199 | 0.020 |
Why?
|
| Hospitalization | 1 | 2011 | 470 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2008 | 99 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2007 | 33 | 0.020 |
Why?
|
| United States | 1 | 2016 | 3939 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2007 | 28 | 0.020 |
Why?
|
| Seizures | 1 | 2008 | 64 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2006 | 32 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2006 | 33 | 0.020 |
Why?
|
| Remission Induction | 1 | 2004 | 84 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2003 | 37 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 263 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 34 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 2002 | 108 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 753 | 0.010 |
Why?
|